Robert R Dorr

US Patent:

20030129208, Jul 10, 2003

Filed:

Jan 7, 2002

Appl. No.:

10/041236

Inventors:

David Alberts - Tucson AZ, US
Robert Dorr - Tucson AZ, US

International Classification:

A61K031/573
A61K009/00

US Classification:

424/400000, 514/179000

Abstract:

Topical alpha-DFMO is mixed with a hydrophillic ointment base, along with at least one additional active drug, for treating actinic keratoses by topical application to human skin tissues. In one case, the topical steroid triamcinolone is combined with the alpha-DFMO. In a second case, the topical non-steroid anti-inflammatory diclofenac is combined with the alpha-DFMO. In a third instance, both triamcinolone and diclofenac are combined with the alpha-DFMO. In all such instances, topical application of such combinations was found to inhibit squamous cell cancer, and the combined effect of such components, when selected in appropriate proportions, in inhibiting squamous cell cancer cells is significantly greater than the effectiveness of each such component by itself.

US Patent:

20040043975, Mar 4, 2004

Filed:

Sep 3, 2003

Appl. No.:

10/655086

Inventors:

David Alberts - Tucson AZ, US
Robert Dorr - Tucson AZ, US

Assignee:

TOPICAL TECHNOLOGIES, INC.

International Classification:

A61K031/573

US Classification:

514/179000

Abstract:

Topical alpha-DFMO is mixed with a hydrophillic ointment base, along with at least one additional active drug, for treating actinic keratoses by topical application to human skin tissues. In one case, the topical steroid triamcinolone is combined with the alpha-DFMO. In a second case, the topical non-steroid anti-inflammatory diclofenac is combined with the alpha-DFMO. In a third instance, both triamcinolone and diclofenac are combined with the alpha-DFMO. In all such instances, topical application of such combinations was found to inhibit squamous cell cancer, and the combined effect of such components, when selected in appropriate proportions, in inhibiting squamous cell cancer cells is significantly greater than the effectiveness of each such component by itself.

US Patent:

20040106588, Jun 3, 2004

Filed:

Sep 3, 2003

Appl. No.:

10/655085

Inventors:

David Alberts - Tucson AZ, US
Robert Dorr - Tucson AZ, US

International Classification:

A61K031/573

US Classification:

514/179000, 514/708000

Abstract:

A method for treating pre-cancerous conditions including non-cancerous lesions and non-invasive carcinoma insitu, in cutaneous, and muco-cutaneous regions of the body includes topical application of combinations containing alpha-DFMO and an anti-inflammatory agent selected from the group comprising a steroidal anti-inflammatory agent, a non-steroidal anti-inflammatory agent, or a combination thereof. The conditions which may be topically treated with the combination of the present invention include actinic keratoses, vulvar neoplasia, and pre-cancerous conditions of the lip, nostrils, nails, and anus. In one case, the topical steroid triamcinolone is combined with the alpha-DFMO. In a second case, the topical non-steroid anti-inflammatory diclofenac is combined with the alpha-DFMO. In a third instance, both triamcinolone and diclofenac are combined with the alpha-DFMO.

US Patent:

20050142078, Jun 30, 2005

Filed:

Feb 25, 2003

Appl. No.:

10/504492

Inventors:

Robert Dorr - Tucson AZ, US
Norman Levine - Tucson AZ, US
Gregory Ertl - Yuma AZ, US
David Alberts - Tucson AZ, US

International Classification:

A61K038/08
A61K007/42

US Classification:

424059000, 514017000

Abstract:

A method of stimulating the production of melanin by the pigment-producing cells (keratinocytes and/or melanocytes) of the skin, in particular for the induction of skin tanning in humans, comprises administering alpha-MSH or an alpha-MSH analogue and exposing the skin to ultraviolet irradiation.

US Patent:

20050176696, Aug 11, 2005

Filed:

Dec 8, 2004

Appl. No.:

11/007988

Inventors:

Robert Dorr - Tucson AZ, US
David Alberts - Tucson AZ, US
Evan Hersh - Phoenix AZ, US

Assignee:

Regents of the University of Arizona - Phoenix AZ

International Classification:

A61K031/396

US Classification:

514183000

Abstract:

The present invention provides compositions useful in treating cancer. The compositions include a synergistic combination of an antineoplastic thiol-binding mitochondrial oxidant with an antineoplastic nucleic acid binding agent, an antineoplastic antimetabolite base analog, or docetaxel. Also provided are methods of assaying the synergistic effects of the combinations and methods of treating cancer using the synergistic combinations.

US Patent:

20070213354, Sep 13, 2007

Filed:

Mar 1, 2007

Appl. No.:

11/681120

Inventors:

Robert Dorr - Tucson AZ, US
Evan Hersh - Tucson AZ, US
David Alberts - Tucson AZ, US

Assignee:

AmpliMed Corporation - Tucson AZ

International Classification:

A61K 31/473

US Classification:

514288000

Abstract:

Compositions and methods for treating multiple sclerosis are disclosed herein. Embodiments of the present invention include methods of treating a multiple sclerosis patient via the administration of a therapeutically effective amount of a composition comprising a compound of the formula: wherein,

US Patent:

20080146653, Jun 19, 2008

Filed:

Dec 6, 2007

Appl. No.:

11/951638

Inventors:

Robert T. DORR - Tucson AZ, US
David S. Alberts - Tucson AZ, US
Evan M. Hersh - Phoenix AZ, US

Assignee:

The Arizona Board of Regents - Phoenix AZ

International Classification:

A61K 31/396
A61K 31/337
A61P 35/04

US Classification:

514449, 514183

Abstract:

The present invention provides compositions useful in treating cancer. The compositions include a synergistic combination of an antineoplastic thiol-binding mitochondrial oxidant with an antineoplastic nucleic acid binding agent, an antineoplastic antimetabolite base analog, or docetaxel. Also provided are methods of assaying the synergistic effects of the combinations and methods of treating cancer using the synergistic combinations.

US Patent:

20080153891, Jun 26, 2008

Filed:

Dec 6, 2007

Appl. No.:

11/951604

Inventors:

Robert T. DORR - Tucson AZ, US
David S. Alberts - Tucson AZ, US
Evan M. Hersh - Phoenix AZ, US

Assignee:

The Arizona Board of Regents - Phoenix AZ

International Classification:

A61K 31/417
A61K 31/396
A61K 31/403
A61P 35/04

US Classification:

514398, 514183, 514410

Abstract:

The present invention provides compositions useful in treating cancer. The compositions include a synergistic combination of an antineoplastic thiol-binding mitochondrial oxidant with an antineoplastic nucleic acid binding agent, an antineoplastic antimetabolite base analog, or docetaxel. Also provided are methods of assaying the synergistic effects of the combinations and methods of treating cancer using the synergistic combinations.